Ustekinumab
- TRADE NAME: Stelara (Centocor)
- INDICATIONS: Plaque psoriasis (moderate to severe); active psoriatic arthritis; active Crohn's disease (moderate to severe)
- CLASS: Antipsoriatic agent, Biologic, Interleukin-12/23 antagonist, Monoclonal antibody
- HALF-LIFE: 15–32 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines, Typhoid Vaccine, Yellow Fever Vaccine
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ustekinumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/14/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric